Ocugen, Inc.

For the period ended Jun 30, 2025. Filed Aug 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 4, 2025

OCGN$0.95-2.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets as of and

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

	June 30, 2025	December 31, 2024
Assets
Current assets
Cash	$27,013	$58,514
Prepaid expenses and other current assets	5,870	3,168
Total current assets	32,883	61,682
Property and equipment, net	15,445	16,554
Restricted cash	312	307
Other assets	4,954	3,899
Total assets	$53,594	82,442
Liabilities and stockholders' equity
Current liabilities
Accounts payable	$4,237	$4,243
Accrued expenses and other current liabilities	12,899	15,500
Operating lease obligations	853	519
Current portion of long term debt	—	1,326
Total current liabilities	17,989	21,588
Non-current liabilities
Operating lease obligations, less current portion	3,945	3,313
Long term debt, net	28,025	27,345
Other non-current liabilities	583	564
Total non-current liabilities	32,553	31,222
Total liabilities	50,542	52,810
Commitments and contingencies (Note 13)
Stockholders' equity
Common stock; $0.01 par value; 390,000,000 shares authorized, 292,313,561 and 291,489,058 shares issued, and 292,192,061 and 291,367,558 shares outstanding at June 30, 2025 and December 31, 2024, respectively	2,924	2,915
Treasury stock, at cost, 121,500 shares at June 30, 2025 and December 31, 2024	(48)	(48)
Additional paid-in capital	370,474	366,938
Accumulated other comprehensive income	12	48
Accumulated deficit	(370,310)	(340,221)
Total stockholders' equity	3,052	29,632
Total liabilities and stockholders' equity	$53,594	$82,442

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

	Three months ended June 30,		Six months ended June 30,
	2025	2024	2025	2024
Collaborative arrangement revenue	$1,373	$1,141	$2,854	$2,155
Total revenue	1,373	1,141	2,854	2,155
Operating expenses
Research and development	8,402	8,902	17,932	15,728
General and administrative	6,766	7,688	13,218	14,092
Total operating expenses	15,168	16,590	31,150	29,820
Loss from operations	(13,795)	(15,449)	(28,296)	(27,665)
Interest (expense) income, net	(1,058)	173	(1,972)	475
Other income (expense), net	114	(4)	179	(14)
Net loss	$(14,739)	$(15,280)	$(30,089)	$(27,204)
Other comprehensive income (loss)
Foreign currency translation adjustment	(28)	3	(36)	8
Comprehensive loss	$(14,767)	$(15,277)	$(30,125)	$(27,196)
Net loss attributable to common shareholders— basic and diluted	(14,739)	(15,259)	(30,089)	(27,157)
Weighted shares used in calculating net loss per common share — basic and diluted	292,067,192	257,353,857	292,032,072	257,293,247
Net loss per share attributable to common shareholders — basic and diluted	$(0.05)	$(0.06)	$(0.10)	$(0.11)
Net loss attributable to Series B Convertible Preferred shareholders — basic and diluted	—	(21)	—	(47)
Weighted shares used in calculating net loss per Series B Convertible Preferred Stock — basic and diluted	—	54,745	—	54,745
Net loss per share attributable to Series B Convertible Preferred shareholders — basic and diluted	—	(0.38)	—	(0.86)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.